GABRA3 and carcinoma: We found that a 7-day treatment regime with these BZDRs (regarded as prolonged treatment under in vitro condition), significantly upregulated GABRA3 in both non-carcinoma MCF10A and carcinoma cells, MCF7 and MDA-MB231 (Fig. 3Q, red boxes).